<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01841554</url>
  </required_header>
  <id_info>
    <org_study_id>CB1-2</org_study_id>
    <nct_id>NCT01841554</nct_id>
  </id_info>
  <brief_title>Cardioband With Transfemoral Delivery System</brief_title>
  <official_title>Cardioband Adjustable Annuloplasty System For Transcatheter Repair of Mitral Valve Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the performance and safety of the Cardioband Adjustable Annuloplasty System for
      repair of functional mitral regurgitation.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety • Overall rate of Major Serious Adverse Events (SAEs) and serious adverse safety</measure>
    <time_frame>30 days</time_frame>
    <description>Overall rate of Major Serious Adverse Events (SAEs)* and serious adverse device effects (SADE) until hospital discharge and at post-operative 30 days.
* Death, myocardial infarction, cardiac tamponade, device related cardiac surgery, stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Performance</measure>
    <time_frame>up to 12 months</time_frame>
    <description>MR Severity at 6 and 12 months
Change in 6 MWT in 6 and 12 months
Change in quality of life (MLHFQ) at 6 and 12 months</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Performance</measure>
    <time_frame>30 days</time_frame>
    <description>Technical success rate of the implantation of the Cardioband
Technical feasibility of Cardioband adjustment
Cardioband ability to reduce mitral valve regurgitation (MR) Intra-procedure, at hospital discharge, and at 30 days.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardioband</intervention_name>
    <arm_group_label>Single</arm_group_label>
    <other_name>With Transfemoral delivery system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Moderate to severe functional MR

          -  Symptomatic Patients (NYHA ClassII-IV) despite optimal medical therapy , including CRT
             if indicated.

          -  LVEF ≥ 25%, LVEDD ≤ 65mm

          -  Subject is high risk to undergo MV surgery (as assessed by a surgeon and a
             cardiologist, at the site)

          -  Transseptal catheterization and femoral vein access is determined to be feasible

          -  Subject is able and willing to give informed consent and follow protocol procedures

        Exclusion Criteria:

          -  Active bacterial endocarditis

          -  Severe organic lesions with retracted chordae or congenital malformations with lack of
             valvular tissue

          -  Heavily calcified annulus or leaflets

          -  Subjects in whom transesophageal echocardiography is contraindicated

          -  Untreated clinically significant CAD requiring revascularization

          -  CRT implant within 3 months prior to procedure

          -  Any percutaneous coronary, carotid, endovascular intervention or carotid surgery
             within 30 days or any coronary or endovascular surgery within 3 months

          -  CVA or TIA within 6 months or severe carotid stenosis (&gt;70% by Ultra sound)

          -  Renal insufficiency requiring dialysis

          -  Life expectancy of less than twelve months

          -  Subject is participating in concomitant research studies of investigational products

          -  Mitral valve anatomy which may preclude proper device treatment

          -  Right-sided congestive heart failure with echocardiographic evidence of severe right
             ventricular dysfunction and severe tricuspid regurgitation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bichat hospital</name>
      <address>
        <city>Paris</city>
        <zip>18 75877</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CardioVasculäres Centrum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik, St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>5 20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum, Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>D-22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätskliniken zu Köln Klinik III Innere Medizin</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Antoniusziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Maisano F, La Canna G, Latib A, Denti P, Taramasso M, Kuck KH, Colombo A, Alfieri O, Guidotti A, Messika-Zeitoun D, Vahanian A. First-in-man transseptal implantation of a &quot;surgical-like&quot; mitral valve annuloplasty device for functional mitral regurgitation. JACC Cardiovasc Interv. 2014 Nov;7(11):1326-8. doi: 10.1016/j.jcin.2014.08.003. Epub 2014 Oct 15.</citation>
    <PMID>25326746</PMID>
  </reference>
  <reference>
    <citation>Maisano F, Taramasso M, Nickenig G, Hammerstingl C, Vahanian A, Messika-Zeitoun D, Baldus S, Huntgeburth M, Alfieri O, Colombo A, La Canna G, Agricola E, Zuber M, Tanner FC, Topilsky Y, Kreidel F, Kuck KH. Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: early results of the feasibility trial. Eur Heart J. 2016 Mar 7;37(10):817-25. doi: 10.1093/eurheartj/ehv603. Epub 2015 Nov 18.</citation>
    <PMID>26586779</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2013</study_first_submitted>
  <study_first_submitted_qc>April 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2013</study_first_posted>
  <last_update_submitted>August 28, 2016</last_update_submitted>
  <last_update_submitted_qc>August 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitral Valve</keyword>
  <keyword>Annuloplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

